Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Study Evaluating Safety and Efficacy of TAR-200 in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy

Trial Profile

A Multicenter Study Evaluating Safety and Efficacy of TAR-200 in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2019

At a glance

  • Drugs Gemcitabine (Primary)
  • Indications Bladder cancer; Carcinoma
  • Focus Adverse reactions
  • Sponsors TARIS Biomedical
  • Most Recent Events

    • 06 Feb 2019 Planned End Date changed from 1 May 2019 to 1 Mar 2020.
    • 06 Feb 2019 Planned primary completion date changed from 1 Jul 2018 to 1 Mar 2020.
    • 14 Mar 2018 According to the TARIS Biomedical media release, dosing has been initiated in this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top